Increased truncated form of plasma tissue factor pathway inhibitor levels in patients with disseminated intravascular coagulation

American Journal of Hematology

Volumn 60, Issue 2, 1999, Pages 94-98

  Shimura, Minori ^a   Wada, Hideo ^a   Nakasaki, Takashi ^a   Hiyoyama, Katsuyo ^a   Mori, Yositaka ^b   Nishikawa, Masakatsu ^a   Deguchi, Hiroshi ^a   Deguchi, Katsumi ^a   Gabazza, Esteban C ^a   Shiku, Hiroshi ^a  

^a MIE UNIVERSITY   (Japan)

^b Mie Red Cross Blood Center   (Japan)

Author keywords

DIC; Intact form; TF; TFPI; Truncated form

Indexed keywords

THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR;

ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DISSEMINATED INTRAVASCULAR CLOTTING; HUMAN; HYPERCOAGULABILITY; PRIORITY JOURNAL; PROTEIN DEGRADATION;

DISSEMINATED INTRAVASCULAR COAGULATION; ENDOPEPTIDASES; HUMANS; LIPOPROTEINS; PEPTIDE FRAGMENTS; SERINE PROTEINASE INHIBITORS;

EID: 0032960667     PISSN: 03618609     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-8652(199902)60:2<94::AID-AJH2>3.0.CO;2-A     Document Type: Article

References (27)

1. Rapaport SI. The extrinsic pathway inhibitor: A regulation of tissue type factor-dependent blood coagulation. Thromb Haemost 1991;66: 6-15.
2. Broze GJ, Warren LA, Novotny WF, Higuchi DA, Girard TJ, Miletich JP. The lipoprotein-associaled coagulation inhibitor that inhibits factor VII-tissue factor complex also inhibits Xa: Insight into its possible mechanism of action. Blood 1988;71:335-343.
3. Bajaj MS, Kuppuswamy MN, Saito H, Spitzer SG, Bajaj SP. Cultured normal human hepatocytes do not synthesize lipoprotein-associated coagulation inhibitor: Evidence that endothelium is the principal site of its synthesis. Proc Natl Acad Sci USA 1990;87:8869-8873.
4. Wun TC, Kretzmer KK, Girard TJ, Miletich JP, Braze GJ. Cloning and characterization of a cDNA coding for the lipoprotein associated co-agulation inhibitor shows that it consists of three tandem Kunitz type inhibitory domains. J Biol Chem 1988;263:6001-6004.
5. Girard TJ, Warren LA, Novotny WF, Likert KM, Brown SG, Meletich JP, Broze GJ. Functional significance of the Kunitz type inhibitory domains of lipoprotein associated coagulation inhibitor. Nature 1989; 338:518-520.
6. Enjyoji K, Miyata T, Kamikubo Y, Kato H. Effect of heparin on the inhibition of factor Xa by tissue factor pathway inhibitor: A segment, Gly 212-Phe 243, of the third Kunitz domain is a heparin binding site. Biochemistry 1995;34:5725-5735.
7. Muller-Berghaus G. Pathophysiologic and biochemical events in disseminated intravascular coagulation: Dysregulation of procoagulant and anticoagulant pathways. Semin Thromb Haemost 1989;15:58-98.
8. Wada H, Ohiwa M, Kaneko T, Tamaki S. Tanigawa M, Shirakawa S, Koyama M, Hayashi T, Suzuki K. Plasma thrombomodulin as a marker of vascular disorders in thrombotic thrombocytopenic purpura and disseminated intravascular coagulation. Am J Hematol 1992;39: 20-24.
9. Weissbach G, Herenberg J, Wendisch J, Pargec N, Thomas K. Tissue factor pathway inhibitor in infants and children. Thromb Res 1994; 73:441-446.
10. Shimura M, Wada H, Wakita Y, Nakase T, Hiyoyama K, Nagaya S, Mori Y, Shiku H. Plasma tissue factor pathway inhibitor levels in patients with disseminated intravascular coagulation. Am J Hematol 1996;52:165-170.
11. Brandtzaeg P, Sandset PM, Joø GB, Øvstevø R, Abildgaard U, Kierulf P. The quantitative association of plasma endotoxin, antithrombin, protein C, extrinsic pathway inhibitor and fibrinopeptide A in systemic meningcoccal disease. Thromb Res 1989;55:459-470.
12. Broze GJ Jr. Tissue factor pathway inhibitor. Thromb Haemost 1995; 74:90-93.
13. Nordfang O, Bjorn SE, Valantin S, Nielsen LS, Wildgoose P, Beck TC, Hedner U. The C-terminal of tissue factor pathway inhibitor is essential to its anticoagulant activity. Biochemistry 1991;30:10371-10376.
14. Wada H, Minamikawa K, Wakita Y, Nakase T, Ohiwa M, Tamaki S, Deguchi K, Shirakawa S, Hayashi T, Suzuki K. Increased vascular endothelial cell markers in patients with disseminated intravascular coagulation. Am J Hematol 1993;44:85-88.
15. Kobayashi N, Maegawa T, Takada M, Tanaka H, Gonmori H. Criteria for diagnosis of DIC based on the analysis of clinical and laboratory findings in 345 DIC patients collected by the Research Committee on DIC in Japan. Bibl Haemotol 1987;49:265-275.
16. Wada H, Minamikawa K, Wakita Y, Nakase T, Ohiwa M, Tamaki S, Deguchi A, Mori Y, Deguchi K, Shirakawa S, Suzuki K. Hemostatic study before onset of disseminated intravascular coagulation. Am J Hematol 1994;43:190-194.
17. Ohno H, Kosaki G, Kambayashi J, Imaoka S, Hirata F. FOY: [ethyl p-(6-guanidinohexanoxyloxy) benzoate] methanesulfonate as a serine protease inhibitor. I. Inhibition of thrombin and factor Xa in vitro. Thromb Res 1980;19:579-588.
18. Ohno H, Kambayashi J, Chang SW, Kosaki G. FOY; [ethyl p-(6-guanidinohexanoxyloxy) benzoate] methanesulfonate as a serine protease inhibitor. II. In vivo effect on coagulofibrinolytic system in comparison with heparin or aprotinin. Thromb Res 1981;24:445-452.
19. Morrissey JH, Fair DS, Edgington TS. Monoclonal antibody analysis of purified and cell-associated tissue factor. Thromb Res 1988;52:247-261.
20. Wada H, Nakase T, Nakaya R, Minamikawa K, Wakita Y, Kaneko T, Ohiwa M, Deguchi K, Shirakawa S. Elevated plasma tissue factor antigen level in patients with disseminated intravascular coagulation. Am J Hematol 1994;45:232-236.
21. Kobayashi M, Wada H, Wakita Y, Shimura M, Nakase T, Hiyoyama K, Nagaya S, Minami N, Nakano T, Shiku H. Decreased plasma tissue factor pathway inhibitor levels in patients with thrombotic thromocytopenia purpura. Thromb Hemost 1995;73:10-14.
22. Gralnick HR, Abrell E. Studies on the procoagulant and fibrinolytic activity of promyelocytic leukemia. Br J Haematol 1973;24:89-98.
23. Wada H, Nagano T, Tomeoku M, Kuto M, Karitani Y, Deguchi K, Shirakawa S. Coagulent and fibrinolytic activities in the leukemic cell lysates. Thromb Res 1982;30:315-322.
24. Warr TA, Rao LVM, Rapaport SI. Human plasma extrinsic pathway inhibitor activity; II plasma levels in disseminated intravascular coagulation and hepatocellular disease. Blood 1989;74:994-998.
25. Sandset PM, Høgevold HE, Lyberg T, Andersson TR, Abildgaard U. Extrinsic pathway inhibitor in elective surgery; A comparison with other coagulation inhibitors. Thromb Haemostas 1989;62:856-860.
26. Novotny WF, Palmier M, Wun T-C, Broze GJ, Miletich JP. Purification and properties of heparin-releasable lipoprotein-associated coagulation inhibitor. Blood 1991;78:394-400.
27. Warshawsky I, Bu G, Mast A, Saffitz JE, Broze GJ Jr, Schwartz AL. The carboxy terminus of tissue factor pathway inhibitor is required for interacting with hepatoma cells in vitro and in vivo. J Clin Invest 1995;95:1773-1781.